Chronic Obstructive Pulmonary Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chronic Obstructive Pulmonary Disease stocks.

Chronic Obstructive Pulmonary Disease Stocks Recent News

Date Stock Title
May 7 AZN UPDATE 1-AstraZeneca to withdraw COVID-19 vaccine globally, Telegraph reports
May 7 GTLS GTLS or CR: Which Is the Better Value Stock Right Now?
May 7 APLS Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
May 7 APLS Apellis Pharmaceuticals (APLS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
May 7 AZN Q1 2024 FibroGen Inc Earnings Call
May 7 APLS Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
May 7 APLS Apellis Pharmaceuticals GAAP EPS of -$0.54 misses by $0.09, revenue of $172.3M beats by $8.04M
May 7 APLS Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
May 7 AZN AstraZeneca concludes equity investment in Cellectis
May 6 GTLS Chart Industries: Record Volumes Grow EBITDA To Ease Debt Concerns
May 6 GTLS Demystifying Chart Industries: Insights From 7 Analyst Reviews
May 6 GTLS Chart Industries First Quarter 2024 Earnings: Misses Expectations
May 6 AZN AstraZeneca invests $140M in Cellectis, raising stake to 44%
May 6 AZN Why Astrazeneca (AZN) is a Top Dividend Stock for Your Portfolio
May 6 APLS Apellis Pharmaceuticals Q1 2024 Earnings Preview
May 6 APGE Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference
May 6 AZN AstraZeneca ups stake in Cellectis in latest cell therapy bet
May 6 APLS Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
May 6 AZN The Zacks Analyst Blog Highlights AstraZeneca, Qualcomm, FedEx, American International and Baker Hughes
May 6 AZN Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time. Eventually everyday activities, such as walking or getting dressed, become difficult. Chronic bronchitis and emphysema are older terms used for different types of COPD. The term "chronic bronchitis" is still used to define a productive cough that is present for at least three months each year for two years.Tobacco smoking is the most common cause of COPD, with factors such as air pollution and genetics playing a smaller role. In the developing world, one of the common sources of air pollution is poorly vented heating and cooking fires. Long-term exposure to these irritants causes an inflammatory response in the lungs, resulting in narrowing of the small airways and breakdown of lung tissue. The diagnosis is based on poor airflow as measured by lung function tests. In contrast to asthma, the airflow reduction does not improve much with the use of a bronchodilator.Most cases of COPD can be prevented by reducing exposure to risk factors. This includes decreasing rates of smoking and improving indoor and outdoor air quality. While treatment can slow worsening, no cure is known. COPD treatments include smoking cessation, vaccinations, respiratory rehabilitation, and often inhaled bronchodilators and steroids. Some people may benefit from long-term oxygen therapy or lung transplantation. In those who have periods of acute worsening, increased use of medications and hospitalization may be needed.As of 2015, COPD affected about 174.5 million (2.4%) of the global population. It typically occurs in people over the age of 40. Males and females are affected equally commonly. In 2015, it resulted in 3.2 million deaths, up from 2.4 million deaths in 1990. More than 90% of these deaths occur in the developing world. The number of deaths is projected to increase further because of higher smoking rates in the developing world, and an aging population in many countries. It resulted in an estimated economic cost of $2.1 trillion in 2010.

Browse All Tags